Drug Profile

IDN 7314

Alternative Names: IDN-7314

Latest Information Update: 18 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Conatus Pharmaceuticals
Developer Histogen
Class Anti-inflammatories; Antineoplastics; Hepatoprotectants
Mechanism of Action Apoptosis inhibitors; Caspase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Primary sclerosing cholangitis
New Molecular Entity Yes

Highest Development Phases

Discontinued Primary sclerosing cholangitis

Most Recent Events

14 Dec 2023 Discontinued - Preclinical for Primary sclerosing cholangitis in USA (PO)
28 Jul 2021 No recent reports of development identified for preclinical development in Primary-sclerosing-cholangitis in USA (PO)
18 Apr 2018 Pharmacodynamics data from a preclinical trial in Primary sclerosing cholangitis released by Conatus Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com